A citation-based method for searching scientific literature

Matias Autio, Suvi-Katri Leivonen, Oscar Brück, Marja-Liisa Karjalainen-Lindsberg, Teijo Pellinen, Sirpa Leppä. Clin Cancer Res 2022
Times Cited: 5







List of co-cited articles
8 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


The immune landscape and response to immune checkpoint blockade therapy in lymphoma.
Justin Kline, James Godfrey, Stephen M Ansell. Blood 2020
74
40

Immune checkpoint inhibitors in lymphoma: challenges and opportunities.
Haris Hatic, Devi Sampat, Gaurav Goyal. Ann Transl Med 2021
8
40


Stromal gene signatures in large-B-cell lymphomas.
G Lenz, G Wright, S S Dave, W Xiao, J Powell, H Zhao, W Xu, B Tan, N Goldschmidt, J Iqbal,[...]. N Engl J Med 2008
40

Clinical and Biological Subtypes of B-cell Lymphoma Revealed by Microenvironmental Signatures.
Nikita Kotlov, Alexander Bagaev, Maria V Revuelta, Jude M Phillip, Maria Teresa Cacciapuoti, Zoya Antysheva, Viktor Svekolkin, Ekaterina Tikhonova, Natalia Miheecheva, Natalia Kuzkina,[...]. Cancer Discov 2021
49
40

Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes.
Bjoern Chapuy, Chip Stewart, Andrew J Dunford, Jaegil Kim, Atanas Kamburov, Robert A Redd, Mike S Lawrence, Margaretha G M Roemer, Amy J Li, Marita Ziepert,[...]. Nat Med 2018
754
40

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Bertrand Coiffier, Eric Lepage, Josette Briere, Raoul Herbrecht, Hervé Tilly, Reda Bouabdallah, Pierre Morel, Eric Van Den Neste, Gilles Salles, Philippe Gaulard,[...]. N Engl J Med 2002
40

clusterProfiler: an R package for comparing biological themes among gene clusters.
Guangchuang Yu, Li-Gen Wang, Yanyan Han, Qing-Yu He. OMICS 2012
40

A Bump in the Road: How the Hostile AML Microenvironment Affects CAR T Cell Therapy.
Rebecca Epperly, Stephen Gottschalk, M Paulina Velasquez. Front Oncol 2020
36
20

Inducible Caspase-9 Selectively Modulates the Toxicities of CD19-Specific Chimeric Antigen Receptor-Modified T Cells.
Iulia Diaconu, Brandon Ballard, Ming Zhang, Yuhui Chen, John West, Gianpietro Dotti, Barbara Savoldo. Mol Ther 2017
140
20

CD40 stimulation leads to effective therapy of CD40(-) tumors through induction of strong systemic cytotoxic T lymphocyte immunity.
Geertje J D van Mierlo, Annemieke Th den Boer, Jan Paul Medema, Ellen I H van der Voort, Marieke F Fransen, Rienk Offringa, Cornelis J M Melief, Rene E M Toes. Proc Natl Acad Sci U S A 2002
183
20

Selinexor: First Global Approval.
Yahiya Y Syed. Drugs 2019
48
20

Trispecific CD19-CD20-CD22-targeting duoCAR-T cells eliminate antigen-heterogeneous B cell tumors in preclinical models.
Dina Schneider, Ying Xiong, Darong Wu, Peirong Hu, Leah Alabanza, Brittany Steimle, Hasan Mahmud, Kim Anthony-Gonda, Winfried Krueger, Zhongyu Zhu,[...]. Sci Transl Med 2021
34
20

Co-expression of CD40/CD40L on XG1 multiple myeloma cells promotes IL-6 autocrine function.
Chunjian Qi, Shengwang Tian, Jiangfang Wang, Hongbin Ma, Keqing Qian, Xueguang Zhang. Cancer Invest 2015
6
20

IL15 Enhances CAR-T Cell Antitumor Activity by Reducing mTORC1 Activity and Preserving Their Stem Cell Memory Phenotype.
Darya Alizadeh, Robyn A Wong, Xin Yang, Dongrui Wang, Joseph R Pecoraro, Cheng-Fu Kuo, Brenda Aguilar, Yue Qi, David K Ann, Renate Starr,[...]. Cancer Immunol Res 2019
124
20

Individual Motile CD4(+) T Cells Can Participate in Efficient Multikilling through Conjugation to Multiple Tumor Cells.
Ivan Liadi, Harjeet Singh, Gabrielle Romain, Nicolas Rey-Villamizar, Amine Merouane, Jay R T Adolacion, Partow Kebriaei, Helen Huls, Peng Qiu, Badrinath Roysam,[...]. Cancer Immunol Res 2015
61
20

The intersection of radiotherapy and immunotherapy: mechanisms and clinical implications.
Michael Spiotto, Yang-Xin Fu, Ralph R Weichselbaum. Sci Immunol 2016
103
20

Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy.
Joshua A Hill, Daniel Li, Kevin A Hay, Margaret L Green, Sindhu Cherian, Xueyan Chen, Stanley R Riddell, David G Maloney, Michael Boeckh, Cameron J Turtle. Blood 2018
242
20

In Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas.
Carlos A Ramos, Rayne Rouce, Catherine S Robertson, Amy Reyna, Neeharika Narala, Gayatri Vyas, Birju Mehta, Huimin Zhang, Olga Dakhova, George Carrum,[...]. Mol Ther 2018
116
20

Blockade of PD-1 immunosuppression boosts CAR T-cell therapy.
Liza B John, Michael H Kershaw, Phillip K Darcy. Oncoimmunology 2013
88
20

Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma.
John H Baird, David J Epstein, John S Tamaresis, Zachary Ehlinger, Jay Y Spiegel, Juliana Craig, Gursharan K Claire, Matthew J Frank, Lori Muffly, Parveen Shiraz,[...]. Blood Adv 2021
37
20

Immunostimulatory oncolytic virotherapy for multiple myeloma targeting 4-1BB and/or CD40.
Jessica Wenthe, Sedigheh Naseri, Ann-Charlotte Hellström, Helena Jernberg Wiklund, Emma Eriksson, Angelica Loskog. Cancer Gene Ther 2020
18
20

DAMP-sensing receptors in sterile inflammation and inflammatory diseases.
Tao Gong, Lei Liu, Wei Jiang, Rongbin Zhou. Nat Rev Immunol 2020
481
20

Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes.
Carlos A Ramos, Brandon Ballard, Huimin Zhang, Olga Dakhova, Adrian P Gee, Zhuyong Mei, Mrinalini Bilgi, Meng-Fen Wu, Hao Liu, Bambi Grilley,[...]. J Clin Invest 2017
213
20

Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells.
Juliane Gust, Kevin A Hay, Laïla-Aïcha Hanafi, Daniel Li, David Myerson, Luis F Gonzalez-Cuyar, Cecilia Yeung, W Conrad Liles, Mark Wurfel, Jose A Lopez,[...]. Cancer Discov 2017
674
20

Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia.
Bianca D Santomasso, Jae H Park, Darin Salloum, Isabelle Riviere, Jessica Flynn, Elena Mead, Elizabeth Halton, Xiuyan Wang, Brigitte Senechal, Terence Purdon,[...]. Cancer Discov 2018
393
20

Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T cell Function against Multiple Myeloma Is Enhanced in the Presence of Lenalidomide.
Melissa Works, Neha Soni, Collin Hauskins, Catherine Sierra, Alex Baturevych, Jon C Jones, Wendy Curtis, Patrick Carlson, Timothy G Johnstone, David Kugler,[...]. Mol Cancer Ther 2019
45
20

A phase I study of anti-BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemia.
Chunrui Li, Wenyue Cao, Yimei Que, Qiuxiang Wang, Yi Xiao, Chaojiang Gu, Di Wang, Jue Wang, Lijun Jiang, Hao Xu,[...]. Clin Transl Med 2021
16
20

CAR T-cells targeting FLT3 have potent activity against FLT3-ITD+ AML and act synergistically with the FLT3-inhibitor crenolanib.
Hardikkumar Jetani, Irene Garcia-Cadenas, Thomas Nerreter, Simone Thomas, Julian Rydzek, Javier Briones Meijide, Halvard Bonig, Wolfgang Herr, Jordi Sierra, Hermann Einsele,[...]. Leukemia 2018
101
20

The potential role of γδ T cells after allogeneic HCT for leukemia.
Rupert Handgretinger, Karin Schilbach. Blood 2018
59
20

Coagulation Disorders after Chimeric Antigen Receptor T Cell Therapy: Analysis of 100 Patients with Relapsed and Refractory Hematologic Malignancies.
Ying Wang, Kunming Qi, Hai Cheng, Jiang Cao, Ming Shi, Jianlin Qiao, Zhiling Yan, Guangjun Jing, Bin Pan, Wei Sang,[...]. Biol Blood Marrow Transplant 2020
27
20

Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial.
Nirav N Shah, Bryon D Johnson, Dina Schneider, Fenlu Zhu, Aniko Szabo, Carolyn A Keever-Taylor, Winfried Krueger, Andrew A Worden, Michael J Kadan, Sharon Yim,[...]. Nat Med 2020
143
20


Bone Marrow Mesenchymal Stromal Cells Can Render Multiple Myeloma Cells Resistant to Cytotoxic Machinery of CAR T Cells through Inhibition of Apoptosis.
Lisa C Holthof, Jort J van der Schans, Afroditi Katsarou, Renée Poels, Anne T Gelderloos, Esther Drent, Susan E van Hal-van Veen, Fengzhi Li, Sonja Zweegman, Niels W C J van de Donk,[...]. Clin Cancer Res 2021
13
20

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.
Jesus G Berdeja, Deepu Madduri, Saad Z Usmani, Andrzej Jakubowiak, Mounzer Agha, Adam D Cohen, A Keith Stewart, Parameswaran Hari, Myo Htut, Alexander Lesokhin,[...]. Lancet 2021
216
20


Characterization of an Anti-CD5 Directed CAR T-Cell against T-Cell Malignancies.
Masayuki Wada, Hongyu Zhang, Liu Fang, Jia Feng, Charlotte Olivia Tse, Wenli Zhang, Qi Chen, Sha Sha, Yuanzhen Cao, Kevin H Chen,[...]. Stem Cell Rev Rep 2020
7
20

A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma.
Di Wang, Jue Wang, Guang Hu, Wen Wang, Yi Xiao, Haodong Cai, Lijun Jiang, Li Meng, Yongkun Yang, Xiaoxi Zhou,[...]. Blood 2021
49
20

Inflammatory cytokines inhibit ADAMTS13 synthesis in hepatic stellate cells and endothelial cells.
W J Cao, M Niiya, X W Zheng, D Z Shang, X L Zheng. J Thromb Haemost 2008
85
20

A quantitative exploration of surface antigen expression in common B-cell malignancies using flow cytometry.
Scott H Olejniczak, Carleton C Stewart, Kathleen Donohue, Myron S Czuczman. Immunol Invest 2006
91
20


Pivotal roles of GM-CSF in autoimmunity and inflammation.
Aoi Shiomi, Takashi Usui. Mediators Inflamm 2015
135
20

Anti-BCMA CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease: A Single Center Analysis of Two Clinical Trials.
Yimei Que, Menglei Xu, Yanjie Xu, Varlene Daniela Fernandes Almeida, Li Zhu, Zhiqiong Wang, Ying Wang, Xian Liu, Lijun Jiang, Di Wang,[...]. Front Immunol 2021
4
25

Anti-CD19 Chimeric Antigen Receptor T Cells in Combination With Nivolumab Are Safe and Effective Against Relapsed/Refractory B-Cell Non-hodgkin Lymphoma.
Yaqing Cao, Wenyi Lu, Rui Sun, Xin Jin, Lin Cheng, Xiaoyuan He, Luqiao Wang, Ting Yuan, Cuicui Lyu, Mingfeng Zhao. Front Oncol 2019
65
20

Molecular basis and therapeutic implications of CD40/CD40L immune checkpoint.
TingTing Tang, Xiang Cheng, Billy Truong, LiZhe Sun, XiaoFeng Yang, Hong Wang. Pharmacol Ther 2021
34
20

Safety and efficacy of CAR-T cell targeting BCMA in patients with multiple myeloma coinfected with chronic hepatitis B virus.
Lu Han, Jian Zhou, Keshu Zhou, Xinghu Zhu, Lingdi Zhao, Baijun Fang, Qingsong Yin, Xudong Wei, Hu Zhou, Linlin Li,[...]. J Immunother Cancer 2020
10
20

4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors.
Adrienne H Long, Waleed M Haso, Jack F Shern, Kelsey M Wanhainen, Meera Murgai, Maria Ingaramo, Jillian P Smith, Alec J Walker, M Eric Kohler, Vikas R Venkateshwara,[...]. Nat Med 2015
884
20

CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity.
Elad Jacoby, Sang M Nguyen, Thomas J Fountaine, Kathryn Welp, Berkley Gryder, Haiying Qin, Yinmeng Yang, Christopher D Chien, Alix E Seif, Haiyan Lei,[...]. Nat Commun 2016
249
20

CD40 Ligand-Modified Chimeric Antigen Receptor T Cells Enhance Antitumor Function by Eliciting an Endogenous Antitumor Response.
Nicholas F Kuhn, Terence J Purdon, Dayenne G van Leeuwen, Andrea V Lopez, Kevin J Curran, Anthony F Daniyan, Renier J Brentjens. Cancer Cell 2019
98
20

Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents.
Carsten Riether, Thomas Pabst, Sabine Höpner, Ulrike Bacher, Magdalena Hinterbrandner, Yara Banz, Rouven Müller, Markus G Manz, Walid H Gharib, David Francisco,[...]. Nat Med 2020
60
20


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.